The National Agency for Food and Drug Administration and Control (NAFDAC) has reminded Nigerians that multi-dose Artemether/Lumefantrine dry powder for oral suspension is no longer approved for registration or use across the country.

In a statement issued on Friday, 27 February 2026, the agency reiterated an earlier regulatory directive released in 2025, stressing that the decision covers all locally produced and imported brands of the multi-dose anti-malaria suspension.

NAFDAC explained that the product was withdrawn because it becomes unstable after being mixed with water, which significantly reduces its effectiveness.

According to the agency, the instability of the reconstituted formulation leads to a loss of efficacy, making the medicine less reliable in treating malaria.

The regulator noted that research indicates that once the drug loses its potency, it may fail to properly treat malaria, potentially resulting in worsening health conditions, treatment failure, severe complications, and in extreme cases, death.

NAFDAC also clarified that it no longer accepts new applications, renewals, or variations for the multi-dose Artemether/Lumefantrine dry powder for oral suspension.

Manufacturers have been directed to instead produce the medication in safer alternatives, including dispersible tablets or single-dose powders or granules packaged in sachets.

The agency further urged healthcare professionals and the public to report any circulation or sale of the discontinued products, as well as any suspected substandard or counterfeit medicines.